Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Gross Margin (2016 - 2025)

Ani Pharmaceuticals (ANIP) has disclosed Gross Margin for 14 consecutive years, with 59.42% as the latest value for Q4 2025.

  • Quarterly Gross Margin rose 154.0% to 59.42% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 61.36% through Dec 2025, up 209.0% year-over-year, with the annual reading at 61.36% for FY2025, 209.0% up from the prior year.
  • Gross Margin hit 59.42% in Q4 2025 for Ani Pharmaceuticals, up from 59.01% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 64.7% in Q2 2025 to a low of 78.44% in Q1 2021.
  • Historically, Gross Margin has averaged 51.48% across 5 years, with a median of 59.21% in 2025.
  • Biggest five-year swings in Gross Margin: crashed -13463bps in 2021 and later soared 12529bps in 2022.
  • Year by year, Gross Margin stood at 44.36% in 2021, then skyrocketed by 39bps to 61.45% in 2022, then dropped by -3bps to 59.42% in 2023, then fell by -3bps to 57.87% in 2024, then rose by 3bps to 59.42% in 2025.
  • Business Quant data shows Gross Margin for ANIP at 59.42% in Q4 2025, 59.01% in Q3 2025, and 64.7% in Q2 2025.